New Thiazolidine-4-One Derivatives as SARS-CoV-2 Main Protease Inhibitors.
COVID-19
SARS-CoV-2
docking studies
main protease
small molecules
thiazolidinone derivatives
Journal
Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453
Informations de publication
Date de publication:
17 May 2024
17 May 2024
Historique:
received:
15
04
2024
revised:
10
05
2024
accepted:
15
05
2024
medline:
25
5
2024
pubmed:
25
5
2024
entrez:
25
5
2024
Statut:
epublish
Résumé
It has been more than four years since the first report of SARS-CoV-2, and humankind has experienced a pandemic with an unprecedented impact. Moreover, the new variants have made the situation even worse. Among viral enzymes, the SARS-CoV-2 main protease (M
Identifiants
pubmed: 38794220
pii: ph17050650
doi: 10.3390/ph17050650
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases
ID : Project no. PE00000007, INF-ACT, Spoke 5